LakeShore Financial Statements From 2010 to 2025

LSBCF Stock   0.84  0.02  2.44%   
LakeShore Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing LakeShore Biopharma's valuation are provided below:
There are over one hundred nineteen available fundamental ratios for LakeShore Biopharma, which can be analyzed over time and compared to other ratios. Active traders should verify all of LakeShore Biopharma last-minute fundamental drivers against the trend between 2010 and 2025 to make sure the company can sustain itself down the road.

LakeShore Biopharma Total Revenue

579.82 Million

Check LakeShore Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LakeShore Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 38.4 M, Interest Expense of 27.1 M or Selling General Administrative of 134.5 M, as well as many indicators such as Price To Sales Ratio of 2.94, Dividend Yield of 0.0 or PTB Ratio of 3.61. LakeShore financial statements analysis is a perfect complement when working with LakeShore Biopharma Valuation or Volatility modules.
  
Build AI portfolio with LakeShore Stock
Check out the analysis of LakeShore Biopharma Correlation against competitors.

LakeShore Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B1.4 B366.2 M
Slightly volatile
Short and Long Term Debt Total382.1 M414.4 M144.1 M
Slightly volatile
Total Current Liabilities578.8 M824.8 M416.3 M
Slightly volatile
Total Stockholder Equity521.8 M499.8 M721.8 M
Slightly volatile
Property Plant And Equipment Net505.2 M414.3 M333.5 M
Slightly volatile
Current Deferred Revenue1.6 M1.5 M2.1 M
Slightly volatile
Accounts Payable53.9 M49.6 M28.9 M
Slightly volatile
Cash26.7 M28.1 M327.3 M
Slightly volatile
Non Current Assets Total444.2 M525.4 M154 M
Slightly volatile
Cash And Short Term Investments26.7 M28.1 M327.3 M
Slightly volatile
Net Receivables426.2 M501.8 M281.8 M
Slightly volatile
Common Stock Shares Outstanding76.9 M123 M45.6 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1.4 B366.2 M
Slightly volatile
Non Current Liabilities Total41 M43.2 M967.4 M
Slightly volatile
Inventory190.2 M227.6 M116.8 M
Slightly volatile
Other Current Assets89 M84.8 M45.5 M
Very volatile
Other Stockholder Equity2.2 BB1.3 B
Slightly volatile
Total Liabilities617.6 M867.9 M214.1 M
Slightly volatile
Total Current Assets941.5 M842.2 M784.6 M
Slightly volatile
Short Term Debt227.3 M390.9 M81.3 M
Slightly volatile
Intangible Assets61.9 M72.9 M80.4 M
Slightly volatile
Common Stock18.3 K28.6 K11.3 K
Slightly volatile
Long Term Debt22.3 M23.5 M217.9 M
Slightly volatile
Capital Lease Obligations434.2 K457 K12.4 M
Slightly volatile
Property Plant And Equipment Gross613.4 M734 M742.4 M
Pretty Stable
Short and Long Term Debt279 M390.4 M157.7 M
Slightly volatile
Capital Stock20.6 K28.6 K11.5 K
Slightly volatile
Net Working Capital16.6 M17.5 M248.7 M
Slightly volatile

LakeShore Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization38.4 M36.7 M30.8 M
Slightly volatile
Interest Expense27.1 M15.7 M28 M
Pretty Stable
Selling General Administrative134.5 M136 M133.4 M
Slightly volatile
Selling And Marketing Expenses224.8 M254.7 M121.3 M
Slightly volatile
Total Revenue579.8 M615 M361.6 M
Slightly volatile
Gross Profit456.6 M507.2 M281.6 M
Slightly volatile
Other Operating Expenses781.4 M701.3 M510.1 M
Slightly volatile
Research Development236.2 M146.4 M140.8 M
Slightly volatile
Cost Of Revenue123.2 M107.8 M80 M
Slightly volatile
Total Operating Expenses658.2 M593.5 M430.1 M
Slightly volatile
Reconciled Depreciation40.3 M36.7 M33.1 M
Slightly volatile

LakeShore Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation17.8 M13.6 M56 M
Slightly volatile
Begin Period Cash Flow281.7 M246.6 M98.9 M
Slightly volatile
Other Cashflows From Financing Activities378.4 M194.9 M577.9 M
Slightly volatile
Depreciation38.4 M36.7 M30.8 M
Slightly volatile
Other Non Cash Items54.8 M48.5 M22.3 M
Slightly volatile
Capital Expenditures17 M17.9 M99.3 M
Pretty Stable
End Period Cash Flow178.5 M107.5 M324.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.943.09151.7909
Slightly volatile
PTB Ratio3.613.803619.2934
Slightly volatile
Days Sales Outstanding217298289
Slightly volatile
Book Value Per Share4.114.6741.8624
Slightly volatile
Average Payables50.2 M58.7 M56.6 M
Pretty Stable
Stock Based Compensation To Revenue0.02090.0220.2104
Slightly volatile
Capex To Depreciation0.460.48733.4056
Slightly volatile
PB Ratio3.613.803619.2934
Slightly volatile
EV To Sales3.533.719250.9173
Slightly volatile
Inventory Turnover0.740.47350.7129
Slightly volatile
Days Of Inventory On Hand455771517
Slightly volatile
Payables Turnover2.952.17493.2978
Slightly volatile
Sales General And Administrative To Revenue0.30.22110.4409
Slightly volatile
Average Inventory140.8 M158.3 M172.6 M
Slightly volatile
Research And Ddevelopement To Revenue0.440.2380.3831
Slightly volatile
Capex To Revenue0.02760.0290.3313
Slightly volatile
Cash Per Share0.250.262710.3861
Slightly volatile
Days Payables Outstanding122168118
Slightly volatile
Income Quality0.71.211.0541
Slightly volatile
Intangibles To Total Assets0.05060.0533630
Slightly volatile
Current Ratio0.971.0212337
Pretty Stable
Receivables Turnover1.51.22551.2684
Slightly volatile
Shareholders Equity Per Share4.444.67421.4927
Slightly volatile
Debt To Equity0.460.82920.2207
Slightly volatile
Capex Per Share0.160.1673.2338
Slightly volatile
Average Receivables378.4 M425.7 M464.1 M
Slightly volatile
Revenue Per Share10.125.75149.0935
Very volatile
Interest Debt Per Share6.584.02293.3334
Slightly volatile
Debt To Assets0.290.303141
Slightly volatile
Operating Cycle6721.1 K806
Very volatile
Price Book Value Ratio3.613.803619.2934
Slightly volatile
Days Of Payables Outstanding122168118
Slightly volatile
Ebt Per Ebit1.691.16961.5342
Very volatile
Company Equity Multiplier2.872.73670.6784
Slightly volatile
Long Term Debt To Capitalization0.04270.04490.0506
Slightly volatile
Total Debt To Capitalization0.260.45330.135
Slightly volatile
Debt Equity Ratio0.460.82920.2207
Slightly volatile
Quick Ratio0.710.7452264
Pretty Stable
Net Income Per E B T0.990.99060.9699
Slightly volatile
Cash Ratio0.03230.0341120
Pretty Stable
Cash Conversion Cycle550901688
Pretty Stable
Days Of Inventory Outstanding455771517
Slightly volatile
Days Of Sales Outstanding217298289
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.091.147631.8034
Pretty Stable
Price To Book Ratio3.613.803619.2934
Slightly volatile
Fixed Asset Turnover0.921.48421.0513
Slightly volatile
Debt Ratio0.290.303141
Slightly volatile
Price Sales Ratio2.943.09151.7909
Slightly volatile
Asset Turnover0.430.44961.9 K
Slightly volatile
Gross Profit Margin0.620.82470.7638
Pretty Stable
Price Fair Value3.613.803619.2934
Slightly volatile

LakeShore Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B1.9 B7.5 B
Slightly volatile
Enterprise Value2.2 B2.3 B7.7 B
Slightly volatile

LakeShore Fundamental Market Drivers

About LakeShore Biopharma Financial Statements

LakeShore Biopharma stakeholders use historical fundamental indicators, such as LakeShore Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although LakeShore Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in LakeShore Biopharma's assets and liabilities are reflected in the revenues and expenses on LakeShore Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in LakeShore Biopharma Co,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.5 M1.6 M
Total Revenue615 M579.8 M
Cost Of Revenue107.8 M123.2 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.22  0.30 
Research And Ddevelopement To Revenue 0.24  0.44 
Capex To Revenue 0.03  0.03 
Revenue Per Share 5.75  10.12 
Ebit Per Revenue(0.14)(0.15)

Currently Active Assets on Macroaxis

When determining whether LakeShore Biopharma Co, is a strong investment it is important to analyze LakeShore Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact LakeShore Biopharma's future performance. For an informed investment choice regarding LakeShore Stock, refer to the following important reports:
Check out the analysis of LakeShore Biopharma Correlation against competitors.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LakeShore Biopharma. If investors know LakeShore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LakeShore Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of LakeShore Biopharma Co, is measured differently than its book value, which is the value of LakeShore that is recorded on the company's balance sheet. Investors also form their own opinion of LakeShore Biopharma's value that differs from its market value or its book value, called intrinsic value, which is LakeShore Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LakeShore Biopharma's market value can be influenced by many factors that don't directly affect LakeShore Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LakeShore Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if LakeShore Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LakeShore Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.